5.13 USD
▼-0.19-3.57%
盘后 5.06 -1.36%
2026-11-19
市值
$395.37M
市盈率
—
EPS
-1.47
股息率
—
52 周区间
4.35 – 14.00
成交量
1.19M
Beta
-0.29
目标价
17.67
52W 低 4.3552W 高 14.00
价格走势
公司简介
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery pl...